Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00402883
Status:
TERMINATED
Last Update Posted:
2021-11-09
First Post:
2006-11-21
Brief Title:
Chemotherapy Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Organization Data
Organization:
SCRI Development Innovations LLC
Class:
OTHER
Study ID:
SCRI LUN 134
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
SCRI Development Innovations LLC
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Eli Lilly and Company | INDUSTRY |
| Genentech Inc | INDUSTRY |